#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Non-small cell lung cancer metastatic Type 2 diabetes mellitus More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Loss of consciousness Hepatobiliary cancer Myxoid liposarcoma Leukoencephalopathy Antisynthetase syndrome Neutropenia Huntington's disease Neuropathic arthropathy Juvenile psoriatic arthritis Methylmalonic acidaemia Central nervous system neoplasm Follicle centre lymphoma follicular grade I II – III refractory Thymic carcinoma Activated PI3 kinase delta syndrome Hyperoxaluria More trials…

    Learn about Rare Diseases

    Encephalitis autoimmune Ocular melanoma – Trials in Disease Lymphatic malformation – Diagnostics Medulloblastoma – Diagnostics Brain stem glioma – Trials in Disease Familial haemophagocytic lymphohistiocytosis Factor VIII deficiency – Basic Information Familial haemophagocytic lymphohistiocytosis – Life with Disease Nephrotic syndrome – Diagnostics Alagille syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sparsentan Azd2693 Sodium Exemestane Tabelecleucel Atl001 GSK4524101A Inclisiran Sodium Resatorvid Pilocarpine Hydrochloride Mecasermin Rinfabate Sot102 Bi-1910 Specific Nucleic Acid Sna-Xfsc Mk-1942 Pemafibrate Vincristine Sulfate Lufepirsen Diclofenac Sodium Emactuzumab Clic-1901 Cart More therapies…

    Learn about Your Condition

    Colorectal adenoma Graft infection Postpartum haemorrhage Endocrine disorder Renal transplant Rectal cancer stage II Electronic cigarette user Synovial sarcoma recurrent Neoplasm malignant Addison's disease Cardiac valve disease Abortion threatened Krabbe's disease Ankylosing spondylitis Cardiac disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Oscar Lambret

Centre Oscar Lambret

3 Rlp Ftjxsyjq Cygjrccroo Larcdp 5wcbwh Fzqjqc

Want to learn more about this study or check if you can participate? Contact us.

  • Study of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment

    Recruiting

    3 1 1
    Investigated Diseases:
    • Gastrointestinal cancer metastatic
    Investigated Drugs:
    • [4-(METHYL-1H-PYRAZOL-4-YL)-BENZYL]-(6[7-(3-PYRROLIDIN-1-YL-PROPOXY)-IMIDAZO[1,2-A]PYRIDIN-3-YL]-PYRIMIDIN-4-YL]-AMINE
    • Sunitinib
    Belgium France Germany Hungary Italy The Netherlands +4

  • Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

    Recruiting

    3 1 1
    Investigated Drugs:
    • [4-(METHYL-1H-PYRAZOL-4-YL)-BENZYL]-(6[7-(3-PYRROLIDIN-1-YL-PROPOXY)-IMIDAZO[1,2-A]PYRIDIN-3-YL]-PYRIMIDIN-4-YL]-AMINE
    • Imatinib Mesilate
    Finland France Germany Greece Hungary Italy +7

  • Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Cabozantinib
    Denmark Finland France Italy The Netherlands Poland +2

  • Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer metastatic
    • Fallopian tube cancer
    • Ovarian cancer
    Investigated Drugs:
    • LY4170156
    • Mirvetuximab Soravtansine
    • Bevacizumab
    Austria Belgium Czechia Denmark France Germany +9

  • A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Bevacizumab
    • Sacituzumab Tirumotecan
    Austria Belgium Czechia Denmark Finland France +9

  • A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    • Bladder cancer
    Investigated Drugs:
    • (S)-4-(4-(3-CHLORO-4-(1-(5-FLUOROPYRIDIN-2-YL)-2-HYDROXYETHOXY)PYRAZOLO[1,5-A]PYRIDIN-6-YL)-5-METHYL-1H-1,2,3-TRIAZOL-1-YL)PIPERIDINE-1-CARBONITRILE
    • Enfortumab Vedotin
    • Pembrolizumab
    Czechia Denmark France Germany Hungary Italy +3

  • Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

    Recruiting

    3 1 1
    Investigated Drugs:
    • Goserelin Acetate
    • Tamoxifen
    • Exemestane
    Belgium Finland France Germany Italy Poland +1

  • Study of inavolisib, ribociclib, and fulvestrant for patients with advanced hormone-receptor-positive, HER2-negative breast cancer.

    Recruiting

    2 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Fulvestrant
    • Inavolisib
    • Ribociclib
    France Germany Italy Poland Spain

  • A study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Prednisone
    • Docetaxel
    Belgium France Germany Italy Spain

  • Evaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Laryngeal squamous cell carcinoma
    • Squamous cell carcinoma of the hypopharynx
    Investigated Drugs:
    • Cetuximab
    • Cisplatin
    • Tretinoin
    Belgium France Italy Poland
1 2 3 … 26
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!